Drugs / Aerosol Sargramostim
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05717140 | Oct 2025 → Jan 2026 | cutaneous melanoma, metastatic malignant neoplasm, metastatic melanoma | Mayo Clinic | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aerosol Sargramostim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05717140 ↗ |
| Modality | Protein / enzyme biologic | “Granulocyte-Macrophage Colony Stimulating Factor (Sargramostim)” NCT05717140 ↗ |
| Route | Inhaled | “Given via inhalation with nebulizer” NCT05717140 ↗ |